Study of NVC-001 for heart muscle disease caused by LMNA gene change
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of dilated cardiomyopathy (a weakened, enlarged heart) linked to a change in the LMNA gene.
- Your heart's pumping strength (LVEF) is between 25% and 45% as measured by an echocardiogram.
- You have a cardiac device (such as an ICD or CRT-D) that has been in place for at least 3 months.
- You have not been hospitalized for heart failure or serious heart rhythm problems in the past 3 months.
- You are not currently using or expected to need IV heart medications on a long-term basis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
This study follows people with a specific genetic change (in the BAG3 gene) that causes heart muscle weakness, to learn more about how the condition progresses over time. It does not test a new drug, but it helps researchers understand the disease better, which may lead to future treatments.
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
This study tests a new medicine called NT-88, which may help improve heart function in people with mild heart failure. It focuses on those with a slightly reduced pumping ability (LVEF 41-49%) and aims to see if the drug is safe and helpful.
Hear when a new LMNA-Related Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.